Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H16N2.ClH |
Molecular Weight | 248.751 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3
InChI
InChIKey=PCCVCJAQMHDWJY-UHFFFAOYSA-N
InChI=1S/C14H16N2.ClH/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14;/h3-6,9-10H,2,7-8H2,1H3,(H,15,16);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H16N2 |
Molecular Weight | 212.2902 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=403065e1-4c1a-433c-bb1b-6a2951946297Curator's Comment: description was created based on several sources, including:
http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116099.pdf
https://www.zoetisus.com/products/dogs/antisedan-_atipamezole_.aspx
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=403065e1-4c1a-433c-bb1b-6a2951946297
Curator's Comment: description was created based on several sources, including:
http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116099.pdf
https://www.zoetisus.com/products/dogs/antisedan-_atipamezole_.aspx
Atipamezole is a synthetic α2-adrenergic antagonist. It competitively inhibits α2-adrenergic receptors. Atipamezole is indicated for the reversal of the sedative and analgesic effects of Dexdomitor and Domitor in dogs. Adverse reactions: occasional vomiting may occur. At times, a period of excitement or apprehensiveness may be seen in dogs treated with atipamezole. Other effects of atipamezole include hypersalivation, diarrhea, and tremors.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095158 |
1.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Antisedan Approved UseIt is indicated for the reversal of the clinical effects of the sedative and analgesic agents. Launch Date1996 |
PubMed
Title | Date | PubMed |
---|---|---|
Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers. | 1991 Feb |
|
A comparative study of the reversal by different alpha 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine. | 1996 Feb |
|
Systemic administration of atipamezole, an alpha 2-antagonist, can reduce scopolamine-induced hyperactivity in rats. | 1997 Oct |
|
Alpha(2A) adrenoceptors contribute to feedback inhibition of capsaicin-induced hyperalgesia. | 2004 Jul |
|
Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice. | 2004 Nov 28 |
|
Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation. | 2005 Feb |
|
Benzo(alpha)pyrene-induced up-regulation of CYP1A2 gene expression: role of adrenoceptor-linked signaling pathways. | 2006 Jun 20 |
|
Seizures during medetomindine sedation and local anaesthesia in two dogs undergoing skin biopsy. | 2009 May |
Patents
Sample Use Guides
The atipamezole dose for the reversal of Dexdomitor or Domitor is 3750 ug/m2 (intravenous) or 5000 ug/m2 (intramuscular).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16389294
Affinity of atipamezole to a1- and a2-adrenoceptors in rat brain membranes is 13,300 and 1.6 nM respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:35:48 GMT 2023
by
admin
on
Fri Dec 15 17:35:48 GMT 2023
|
Record UNII |
2W4279571X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
13649426
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | |||
|
C80011
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | |||
|
DBSALT001642
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | |||
|
390043
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
m2122
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
104075-48-1
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | |||
|
2W4279571X
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | |||
|
300000029152
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | |||
|
DTXSID2048583
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY | |||
|
2W4279571X
Created by
admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |